Company intelligence / Profile preview

Jinwei

Shanghai, Shanghai, Chinajinwei-food.com ↗

Ownership: Private
Development stage: Commercial

Overview

Jinwei is developing first-in-class therapies using proprietary lentiviral vector and cryptic peptide platforms targeting oncology and infectious diseases. Their vectors have been used in early-phase clinical trials for HIV and are approved for HPV clinical studies. The company also acts as a CDMO with GMP-compliant manufacturing capabilities.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Lentiviral vectorViral vectorCell therapyPeptides
Industry: Biotech

Partnerships

TheraVectysPasteur InstituteHuashan HospitalMinistry of Science & Technology of ChinaChina National Health Commission

Beyond the preview

Go deeper on Jinwei.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jinwei.

Explore the full profile